Spots Global Cancer Trial Database for Isolated Liver Perfusion With Oxaliplatin
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Isolated Liver Perfusion With Oxaliplatin
Official Title: A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases
Study ID: NCT01042691
Conditions
Interventions
Study Description
Brief Summary: The primary goal of this research study is to determine a safe dose for the drug oxaliplatin when delivered by isolated hepatic perfusion. The second goal of this research study is to determine if isolated hepatic perfusion with oxaliplatin can improve the efficacy of standard hepatic arterial infusional (HAI) therapy with floxuridine (FUDR)/leucovorin.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
UPMC Cancer Centers, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
UPMC Shadyside, Pittsburgh, Pennsylvania, United States
Contact Details
Name: David L Bartlett, M.D.
Affiliation: University of Pittsburgh
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
